Repotrectinib
Chemical formula: C₁₈H₁₈FN₅O₂ Molecular mass: 355.144 g/mol PubChem compound: 135565923
Active ingredient description
Repotrectinib is an inhibitor of proto-oncogene tyrosine-protein kinase ROS1, the tropomyosin receptor tyrosine kinases (TRK) TRKA, TRKB, TRKC, and anaplastic lymphoma kinase (ALK). Repotrectinib has demonstrated in vitro and in vivo inhibition of cell lines expressing the targeted fusion oncogenes ROS1, TRKA, TRKB, TRKC, and corresponding mutations (ROS1G2032R, ROS1D2033N, TRKAG595R, TRKBG639R, TRKCG623R).
Medicine classification
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L01EX28 | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors | |
Product monographs
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| AUGTYRO Capsule | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| AUGTYRO Capsule, hard | European Medicines Agency (EU) | MPI, EU: SmPC |
Medicines
Repotrectinib is an active ingredient of these brands:
United States (US)Lithuania (LT)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.